Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

CAR T-cells effective agst myeloma

CAR T-cells effective agst myeloma

First time revolutionary therapy used in Italy

Bologna, 20 December 2018, 17:47

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

For the first time in Italy, treatment using CAR T-cells has been used against multiple myeloma.
    The therapy is considered revolutionary.
    The treatment was given at the Sant'Orsola polyclinic in Bologna, where one patient has already been released from the hospital and another is currently receiving it. T-cells are extracted from the patient's blood, modified genetically with the addition of an artificial receptor (called a "chimeric antigen receptor", or CAR) to their surface. The receptor enables the modified cells to produce chemicals that kill cancer. Once infused back into a patient's body, they begin multiplying and attacking tumor cells.
    The therapy was given by a medical team under Professor Michele Cavo. The treatment is considered a new approach in the fight against cancer and is for the time being used only in certain types of blood cancer.
    Studies conducted and published on one strain of acute leukemia and lymphoma have shown exceptional effectiveness of the treatment, which was recently approved by the FDA and EMA, the regulatory bodies for pharmaceuticals in the US and Europe. The Sant'Orsola hospital is one of two Italian centers selected to conduct the first experimental study with CAR T-cells in multiple myeloma.
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.